BioMoti is based at The Queen Mary BioEnterprises Innovation Centre and maintains solid links with Barts and The London including access to world-class researchers and facilities. BioMoti works in a capital efficient manner with a range of expert consultants, business and clinical advisors as well as legal and financial professionals.
Keith has been in biotechnology since it started. Having worked for GSK and ICI/Zeneca in genetics/molecular biology he led several large groups including discovery and finally running the patent group. He then worked at Maxygen on the West Coast leading the small molecule group through the IPO and growing a business that eventually spun out as ‘Codexis’. On returning to the UK, Keith joined the Bloomsbury BioSeed Fund and Longbow Capital and acted as CEO for several portfolio companies. He led Domainex through a merger with NCE to form a successful business in protein structure-based chemistry and Polytherics was built through organic growth since 2005 to be now part of the listed Abzena group of companies. Keith is currently chairman of Domainex and Canbex and has a range of other Board interests in the healthcare industry.
Davidson Ateh is an entrepreneurial executive with a successful track record of managing and financing disruptive early stage technology projects. He is the CEO of BioMoti where he raised over £1.5 million in non-dilutive and risk capital including securing a number of alliances. He is an inventor of and has progressed BioMoti’s innovative Oncojan™ cancer therapeutics platform, leading on preclinical development, clinical planning, financial modelling, market research, commercial plans, business development, venture pitching, regulatory compliance, staff, team building, external contractors and partnerships with major pharma companies. He has an interdisciplinary background in the physical and life sciences with a BEng in Biomedical Materials and a PhD in Bioengineering. He was a recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship during which he had a year of business training at the endowed Hunter Centre for Entrepreneurship of Strathclyde Business School.
Jo is the Director of Academic Health Sciences (and Consultant Histopathologist) at Barts Health NHS Trust and Professor of Pathology at Queen Mary University of London. She was previously NHS National Clinical Director of Pathology and is currently the President-Elect of The Royal College of Pathologists (she will take up the role from November 2017). Jo has an international reputation in the study of diseases with over 115 publications including high impact journals such as Science and Nature. She is an experienced business leader (MA in Leadership) with a track record of running a large NHS Trust Division (£89 million budget per annum), delivering and commissioning a £40 million building, and 2 major IT system implementations (both over £1.3 million). She has an excellent understanding of technology transfer previously been an assessor of early stage technologies for Nikko Principal Investments Ltd. Jo is a co-inventor of the Oncojan™ cancer therapeutics platform, co-founder and on the board of BioMoti.